Integrum raises $2.3 million to push OPRA implant into US and Ukraine
What's the deal? Sweden's IntegrumDealroom has a profile for this one. Try Dealroom → has completed a directed issue of 2,666,791 Class B shares at US$1.04 each, raising roughly US$2.77M before costs. The medical device maker sells the OPRA Implant System, an osseointegration technology that anchors prosthetic limbs directly to bone.
Who's backing it? New institutional investors Cicero FonderDealroom has a profile for this one. Try Dealroom →, Nowo Fund Management, Curam HoldingDealroom has a profile for this one. Try Dealroom →, Förvaltnings AB Grötlingboudd, Exelity ABDealroom has a profile for this one. Try Dealroom →, and individuals Maria Anderkvist and Fredrik Lundgren joined existing shareholder Nordic Compound InvestDealroom has a profile for this one. Try Dealroom →. All shares were subscribed and allotted.
What's the money for? Integrum plans to accelerate commercialisation of OPRA, primarily in the US, pursue an opening in Ukraine, and fund selected strategic initiatives.
Why now? The company says its new patient portal and sales organisation have built momentum in the US, and Ukrainian authorities have decided to invest in osseointegration to help war-injured patients. The capital gives it flexibility to act on both.
What's the endgame? Integrum has shifted toward a leaner, commercially focused organisation over the past year. It aims to deepen penetration around Centers of Excellence in existing markets while selectively expanding into new ones.
"This capital injection now gives us greater flexibility to capitalize on these positive developments and accelerate the commercialization of the OPRA Implant System," said Martin Hillsten, president and chief executive officer.
The signal: A modest post-IPO raise from committed institutional and existing backers points to disciplined capital allocation over aggressive fundraising — enough runway to press two specific openings, the US market and Ukraine, without diluting further than needed.
Read more: placera.se
Image credit: NavyMedicine
